Medtronic reported Q2 FY2025 revenue of $8.403 billion, increasing 5.3% as reported and 5.0% organic. GAAP diluted EPS reached $0.99, up 46%, while non-GAAP diluted EPS was $1.26. The company demonstrated strong performance across multiple franchises, including TAVR, PFA, Leadless Pacemakers, Diabetes, Spine, and Neuromodulation.Growth was driven by the Cardiovascular Portfolio (+6.1%), Neuroscience Portfolio (+7.1%), and Diabetes (+12.4%). The Medical Surgical Portfolio showed modest growth of 1.2%. Geographic performance remained robust with International revenue growing 7.6% and U.S. revenue up 3.1%.Based on strong performance, Medtronic raised its FY2025 guidance, with organic revenue growth now expected at 4.75% to 5% (up from 4.5% to 5%) and non-GAAP diluted EPS projected at $5.44 to $5.50. The company anticipates high-single digit adjusted EPS growth in the second half of the fiscal year.

Medtronic reported Q2 FY2025 revenue of $8.403 billion, increasing 5.3% as reported and 5.0% organic. GAAP diluted EPS reached $0.99, up 46%, while non-GAAP diluted EPS was $1.26. The company demonstrated strong performance across multiple franchises, including TAVR, PFA, Leadless Pacemakers, Diabetes, Spine, and Neuromodulation.Growth was driven by the Cardiovascular Portfolio (+6.1%), Neuroscience Portfolio (+7.1%), and Diabetes (+12.4%). The Medical Surgical Portfolio showed modest growth of 1.2%. Geographic performance remained robust with International revenue growing 7.6% and U.S. revenue up 3.1%.Based on strong performance, Medtronic raised its FY2025 guidance, with organic revenue growth now expected at 4.75% to 5% (up from 4.5% to 5%) and non-GAAP diluted EPS projected at $5.44 to $5.50. The company anticipates high-single digit adjusted EPS growth in the second half of the fiscal year.